This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
Complete resection is difficult to achieve without damaging the main organs in advanced thymoma or thymic carcinoma. The previous trials have showed that radiotherapy was significantly associated with prolonged OS and chemotherapy is playing an increasing role in treatment of patients with advanced thymoma or thymic carcinoma. However, whether concurrent chemoradiotherapy is safety in advanced thymoma or thymic carcinoma is still unknown. The purpose of this study is to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
56
The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
Kailiang Wu
Shanghai, Shanghai Municipality, China
Objective response rate
Evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria
Time frame: 3 months after treatment
Overall survival
from registration to death as a result of any cause.
Time frame: 2 years
Progression free survival
from registration to first documentation of disease progression or death.
Time frame: 2 years
Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0
Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.